Vol. 2 No. 5 (2022)
Health Technology Reviews

Aprepitant for the Prevention of Post-Operative Nausea and Vomiting in Refractory or High-Risk Patients

Published May 30, 2022

Key Messages

  • No studies were found that evaluated the clinical effectiveness of aprepitant for the prevention of post-operative nausea and vomiting in patients with a history of post-operative nausea and vomiting refractory to conventional antiemetic prophylaxis that met the criteria for this review.
  • In patients with the potential for life-threatening post-operative medical complications due to emesis, limited evidence of variable quality was identified for the clinical effectiveness of aprepitant. The studies varied by population, the combination of interventions and comparators and the outcomes measured, and the findings were mixed.
  • No studies were found that evaluated the cost-effectiveness of aprepitant for the prevention of post-operative nausea and vomiting in patients with a history of post-operative nausea and vomiting refractory to conventional antiemetic prophylaxis that met the criteria for this review.
  • No studies were found that evaluated the cost-effectiveness of aprepitant for the prevention of post-operative nausea and vomiting in patients with the potential for life-threatening post-operative medical complications due to emesis that met the criteria for this review.
  • No evidence-based guidelines were found regarding the use of aprepitant for the prevention of post-operative nausea and vomiting in patients with a history of post-operative nausea and vomiting refractory to conventional antiemetic prophylaxis that met the criteria for this review.
  • No evidence-based guidelines were found regarding the use of aprepitant for the prevention of post-operative nausea and vomiting in patients with the potential for life-threatening post-operative medical complications due to emesis that met the criteria for this review.